← Back to Search

Anti-fungal

Boric Acid + Fluconazole for Vaginal Yeast Infections (THRIVE-yeast Trial)

Phase < 1
Recruiting
Led By Aleeza Gerstein, PhD
Research Sponsored by University of Manitoba
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female between ages of 18 and 50 years
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one month
Awards & highlights

THRIVE-yeast Trial Summary

This trial is studying two drugs commonly used to treat vaginal yeast infections to see how well they work in women with vaginal yeast infections that keep coming back.

Who is the study for?
This trial is for Canadian females aged 18-50 who have a yeast infection, also known as vulvovaginal candidiasis. It's not open to those who are pregnant, trying to conceive, or have had a hysterectomy.Check my eligibility
What is being tested?
The study compares the effectiveness of boric acid suppositories and fluconazole (a common antifungal medication) in treating yeast infections and preventing recurrence by examining changes in vaginal microbial communities.See study design
What are the potential side effects?
Fluconazole can cause headaches, nausea, abdominal pain, and skin rash. Boric acid may lead to watery discharge or local irritation. Side effects vary from person to person.

THRIVE-yeast Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman aged between 18 and 50.

THRIVE-yeast Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one month
This trial's timeline: 3 weeks for screening, Varies for treatment, and one month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Fungal Diversity
Secondary outcome measures
Bacterial Diversity
Host Functional Changes

THRIVE-yeast Trial Design

3Treatment groups
Active Control
Group I: Recurrent Infection Cohort - symptomaticActive Control2 Interventions
Participants with a history of recurrent vulvovaginal candidiasis infections who have an active symptomatic infection when they come to clinic
Group II: Asymptomatic CohortActive Control1 Intervention
Participants with no history of vulvovaginal candidiasis
Group III: Recurrent Infection Cohort - asymptomaticActive Control1 Intervention
Participants with a history of recurrent vulvovaginal candidiasis infections who do not have an active symptomatic infection when they come to clinic

Find a Location

Who is running the clinical trial?

Manitoba Medical Service FoundationOTHER
18 Previous Clinical Trials
961 Total Patients Enrolled
Research ManitobaOTHER
11 Previous Clinical Trials
17,317 Total Patients Enrolled
University of ManitobaLead Sponsor
593 Previous Clinical Trials
199,283 Total Patients Enrolled

Media Library

Fluconazole 150 mg (Anti-fungal) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04930107 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research available to those aged 85 or younger?

"According to the screening requirements, individuals aged 18-50 are eligible for enrollment in this clinical trial."

Answered by AI

Are there any available slots in this clinical trial for volunteers?

"Patient recruitment for this medical trial is still ongoing, as evidenced by the information hosted on clinicaltrials.gov. The study was created on December 7th 2021 and last updated February 7th 2022."

Answered by AI

To what illnesses is the Assumed First-Time Infection Cohort typically applied?

"All three conditions of candida intertrigo, skin disinfection therapy and candidiasis can be efficiently managed with the Assumed First-Time Infection Cohort."

Answered by AI

Could I potentially be a participant in this research endeavor?

"This clinical trial seeks 105 female participants, aged 18 to 50 years old, who have been diagnosed with vaginitis monilial. To be eligible for the study, these are the required criteria."

Answered by AI

How many participants have enrolled in this research trial?

"Yes, according to clinicaltrials.gov, this study is currently recruiting patients. This trial was initially released on December 7th 2021 and last updated on February 7th 2022. 105 subjects are needed for this single-location research project."

Answered by AI
~34 spots leftby Apr 2025